Dosage of sugammadex according to the calculated lean body mass in obese female patients: time to reverse moderate neuromuscular blockade induced by rocuronium

References

• Leykin Y, Pellis T, Lucca M, et al. The pharmacodynamic effects of rocuronium when dosed according to real body weight or ideal body weight in morbidly obese patients. Anesth Analg. 2004;99(4):1086–1089. doi: 10.1213/01.ANE.0000120081.99080.C2
   PubMed Web of Science ®Google Scholar
• Kopman A. Sugammadex: a revolutionary approach to neuromuscular antagonism. Anesthesiology. 2006;104:631–633. doi: 10.1097/00000542-200604000-00003
   PubMed Web of Science ®Google Scholar
• Plaud B, Meretoja O, Hofmockel R, et al. Reversal of rocuronium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients. Anesthesiology. 2009;110(2):284–294.
   PubMed Web of Science ®Google Scholar
• Debaene B, Meistelman C. Indications et utilisation clinique du sugammadex. Annales Françaises D'Anesthésie et de Réanimation. 2009;28:S57–S63. doi: 10.1016/S0750-7658(09)72489-X
   PubMedGoogle Scholar
• De Baerdemaeker LEC, Mortier EP, Struys MMRF. Pharmacokinetics in obese patients. Continuing Education in anaesthesia. Crit Care Pain. 2004;4(5):152–155.
   Google Scholar
• Suy K, Morias K, Cammu G. Effective reversal of moderate rocuronium or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent. Anesthesiology. 2007;106:283–288. doi: 10.1097/00000542-200702000-00016
   PubMed Web of Science ®Google Scholar
• Groudine SB, Soto R, Lien C, et al. A randomized, dose-finding, Phase II study of the selective relaxant binding drug, sugammadex, Capable of Safely reversing Profound rocuronium-induced neuromuscular block. Anesth Analg. 2007;104(3):555–562. doi: 10.1213/01.ane.0000260135.46070.c3
   PubMed Web of Science ®Google Scholar
• Sorgenfrei IF, Norrid K, Larsen PB. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. Anesthesiology. 2006;104:667–674. doi: 10.1097/00000542-200604000-00009
   PubMed Web of Science ®Google Scholar
• Meyhoff C.S, Lund J, Jenshup MT, et al. Should dosing of rocuronium in obese patients Be based on ideal or corrected body weight? Anesth Analg. 2009;109(3):787–792. doi: 10.1213/ane.0b013e3181b0826a
   PubMed Web of Science ®Google Scholar
• Püringer FK, Keller C, Kleinasser A, et al. Pharmacokinetics of rocuronium bromide in obese female patients. Eur J Anaesthesiol. 1999;16(8):507–510. doi: 10.1046/j.1365-2346.1999.00523.x
   PubMed Web of Science ®Google Scholar
• Murphy G, Szokol J, Marymont J, et al. Intraoperative Acceleromyographic monitoring Reduces the Risk of residual neuromuscular blockade and Adverse Respiratory Events in the Postanesthesia Care Unit. Anesthesiology. 2008;109(3):389–398. doi: 10.1097/ALN.0b013e318182af3b
   PubMed Web of Science ®Google Scholar
• Kopman A, Yee P, Neuman G. Relationship of the train-of-four Fade ratio to clinical Signs and Symptoms of residual Paralysis in Awake Volunteers. Anesthesiology. 1997;86:765–771. doi: 10.1097/00000542-199704000-00005
   PubMed Web of Science ®Google Scholar
• Stout RG, Gan TJ, Glass PS, et al. The effect of desflurane on rocuronium onset, clinical duration and maintenance requirements. Acta Anaesthesiol Belg. 2006;57(4):349–353.
   PubMedGoogle Scholar
• Wulf H, Ledowski T, Linstedt U, et al. Neuromuscular blocking effects of rocuronium during desflurane, isoflurane, and sevoflurane anaesthesia. Can J Anaesth. 1998;45(6):526–532. doi: 10.1007/BF03012702
   PubMed Web of Science ®Google Scholar
• Maidatsi PG, Zaralidou AT, Gorgias NK, et al. Rocuronium duration of action under sevoflurane, desflurane or propofol anaesthesia. Eur J Anaesth. 2004 Oct;21(10):781–786. doi: 10.1097/00003643-200410000-00005
   PubMed Web of Science ®Google Scholar
• Vanacker B, Vermyen K, Struys M, et al. Reversal of rocuronium-induced neuromuscular block with the Novel drug sugammadex Is Equally effective Under maintenance Anesthesia with propofol or sevoflurane. Anaesth Analg. 2007;104:563–568. doi: 10.1213/01.ane.0000231829.29177.8e
   PubMed Web of Science ®Google Scholar
• Beaufort AM, Wierda JM, Belopavlovic M, et al. The influence of hypothermia (surface cooling) on the time-course of action and on the pharmacokinetics of rocuronium in humans. Eur J Anaesthesiol. Supplement. 01 Sep 1995;11:95–106.
   Google Scholar
• Mirakhur RK. Sugammadex in clinical practice. Anaesthesia. 2009;64(suppl 1):45–54. doi: 10.1111/j.1365-2044.2008.05870.x
   PubMed Web of Science ®Google Scholar
• Monk TG, Rietbergen H, Woo T, et al. Use of sugammadex in patients With obesity: A Pooled analysis. Am J Ther. 2017 Sep/Oct;24(5):e507–e516. doi: 10.1097/MJT.0000000000000305
   PubMed Web of Science ®Google Scholar
• Duarte NMDC, Caetano AMM, Neto SDSC, et al. Sugammadex by ideal body weight versus 20% and 40% corrected weight in bariatric surgery – double-blind randomized clinical trial. Brazil J Anesth. May–June 2018;68(3):219–224. doi: 10.1016/j.bjan.2017.10.010
   Google Scholar
• Van Lancker P, Dillemans B, Bogaert T, et al. Ideal versus corrected body weight for dosage of sugammadex in morbidly obese patients. Anaesthesia. 2011;66(8):721–725. doi: 10.1111/j.1365-2044.2011.06782.x
   PubMed Web of Science ®Google Scholar
• Sperry R. Principles of economic analysis. Anesthesiology. 1997;86:1197–1205. doi: 10.1097/00000542-199705000-00022
   PubMed Web of Science ®Google Scholar
• Johnstone RE, Jozefczyk KG. Cost of anesthetic drugs. Experience with a cost education trial. Anesth Analg. 1994;76:766–771.
   Google Scholar